CSL (ASX:CSL) has attracted fresh attention after its Broadmeadows plasma fractionation facility in Australia was named the Overall Winner of the 2025 Facility of the Year Award by the International Society for Pharmaceutical Engineering.

This prestigious recognition highlights CSL's adoption of advanced automation, real-time monitoring, robotics, and digital twin technology. These developments have enabled a significant increase in production capacity and efficiency at the site.

See our latest analysis for CSL.

CSL’s 2025 Facility of the Year Award comes after a turbulent stretch for the company, including shareholder scrutiny over executive pay and a sharp drop in market value. Despite recent highs, CSL’s 1-year total shareholder return sits at -26.2%, reflecting lingering concerns about revenue and regulatory headwinds. Even so, investors watching the latest innovations may see early signs of renewed momentum building for the long run.

If you’re keen to find more companies innovating in the space, now is a great opportunity to discover See the full list for free.

With CSL trading at a substantial discount to analyst targets after a year of setbacks and innovation headlines, the question is whether the market is undervaluing the company’s prospects or has already accounted for its future growth.

Most Popular Narrative: 24.7% Undervalued

With the most recent consensus fair value for CSL set at A$280.61, shares closed last at A$211.42, putting them notably below what analysts see as justified. Strong assumptions about future earnings and margin expansion are key factors driving this discrepancy, attracting keen interest from those following the narrative.

CSL is undertaking significant operational transformation initiatives, targeting over $0.5 billion in cost savings by FY28. The company is focusing on increased efficiency in plasma collection, manufacturing, and R&D, which should expand margins and support stronger net earnings growth as these benefits are realized. CSL is leveraging advances in biotechnology, with a refreshed late-stage pipeline (including gene therapies and high-margin products like ANDEMBRY and HEMGENIX), and plans to reinvest around half of cost savings into innovation and clinical development. This may potentially accelerate top-line revenue growth from new product launches benefiting from increased acceptance and effectiveness of biologic and precision therapies.

Read the complete narrative.

What’s behind this valuation gap? It centers on a bold upgrade in future margins and ambitious launches that could accelerate top-line growth. The full narrative reveals which blockbuster product bets, operational changes, and financial shifts form the foundation for this fair value—details you won’t want to miss.

Story Continues

Result: Fair Value of $280.61 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, persistent regulatory risks and slow uptake of new product launches could present challenges to CSL’s recovery narrative and limit anticipated long-term earnings growth.

Find out about the key risks to this CSL narrative.

Build Your Own CSL Narrative

If you have a different perspective or prefer your own research approach, you can quickly create a fresh narrative from the data in just a few minutes. Do it your way

A good starting point is our analysis highlighting 4 key rewards investors are optimistic about regarding CSL.

Looking for more investment ideas?

Stay ahead of the market by acting now. Open doors to fresh opportunities beyond CSL and position yourself for your next breakthrough investment move.

Spot those hidden gems showing strong financials early by checking out these 3556 penny stocks with strong financials, where potential high-return stocks wait for savvy investors. Access market-beating income potential and secure your portfolio with these 17 dividend stocks with yields > 3%, highlighting companies delivering stable yields above 3%. Jump into a booming sector and track leading-edge advancements through these 27 AI penny stocks, featuring pioneers in artificial intelligence with real-world momentum.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include CSL.AX.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments